[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350486-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-350486-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","association-between-endocrine-therapy-and-survival-outcomes-in-estrogen-receptorlow-breast-cancer-a-systematic-review-and-meta-analysis","Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer - a systematic review and meta-analysis","","Background: The clinical significance of endocrine therapy (ET) in patients with estrogen receptor–low (ER-low, 1%-10%) breast cancer remains uncertain. Increasing evidence suggests these tumors differ biologically from typical hormone receptor–positive cancers, raising questions about ET benefit. Methods: A systematic review and meta-analysis followed PRISMA 2020, searching PubMed, Embase, Cochrane Library, and Web of Science to July 1, 2025. Hazard ratios with 95% CIs were extracted or estimated from Kaplan–Meier curves. Results: Six retrospective studies (8765 patients) showed ET improved overall survival (HR 0.81, 95% CI 0.69-0.95) and disease-free survival (HR 0.64, 95% CI 0.45-0.90). Conclusions: ET was associated with improved outcomes in ER-low disease, supporting cautious consideration rather than uniform omission.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/association-between-endocrine-therapy-and-survival-outcomes-in-estrogen-receptorlow-breast-cancer-a-systematic-review-and-meta-analysis/350486/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/association-between-endocrine-therapy-and-survival-outcomes-in-estrogen-receptorlow-breast-cancer-a-systematic-review-and-meta-analysis/350486.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical question does the review address?","Question",{"text":63,"@type":64},"It evaluates the clinical significance of endocrine therapy for patients with estrogen receptor–low breast cancer, where benefit has been uncertain.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies identified and analyzed?",{"text":68,"@type":64},"The review followed PRISMA 2020 and searched PubMed, Embase, the Cochrane Library, and Web of Science up to July 1, 2025. Effect sizes were synthesized using random-effects models and hazard ratios were extracted or estimated from Kaplan–Meier curves.",{"name":70,"@type":61,"acceptedAnswer":71},"What survival benefits were reported for endocrine therapy?",{"text":72,"@type":64},"Endocrine therapy was associated with improved overall survival (HR 0.81, 95% CI 0.69-0.95) and disease-free survival (HR 0.64, 95% CI 0.45-0.90).",{"name":74,"@type":61,"acceptedAnswer":75},"Why should endocrine therapy not be routinely omitted in ER-low breast cancer?",{"text":76,"@type":64},"The findings suggest improved OS and DFS, and the authors caution against uniform endocrine-insensitive assumptions. They also note evidence is based on retrospective observational studies, warranting further prospective research.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},350486,1790182345,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":122,"preview_page_count":33,"preview_urls":149},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","The Oncologist, 2026, 31, oyag230  \n[https://doi.org/10.1093/oncolo/oyag230](https://doi.org/10.1093/oncolo/oyag230)  \n[Published: June 10](Published: June 10), 2026  \nReview Article  \nAssociation between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer: a systematic review and meta-analysis  \nFan Xia1,2,3, XiaoBo Hu4,5,6, Lei Zhang7, XiaoDong Peng1,2,3,†, Mei Xie4,5,6,*,†,   \n1 Department of Oncology, West China School of Medicine, Sichuan University, Chengdu, 610000, China 2 Department of Oncology, Sichuan University Affiliated Chengdu Second People’s Hospital, Chengdu, 610000, China 3 Department of Oncology, Chengdu Second People’s Hospital, Chengdu, 610000, China  \n4 Department of Respiratory and Critical Care Medicine, West China School of Medicine, Sichuan University, Chengdu, 610000, China 5 Department of Respiratory and Critical Care Medicine, Sichuan University Affiliated Chengdu Second People’s Hospital, Chengdu, 610000, China 6 Department of Respiratory and Critical Care Medicine, Chengdu Second People’s Hospital, Chengdu, 610000, China  \n7 Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610000, China  \n*Corresponding author: Mei Xie, Department of Respiratory and Critical Care Medicine, West China School of Medicine, Sichuan University, No. 10 Qingyun Street, Jinjiang District, Chengdu, 610000, Sichuan Province, China ([xiemei0801@163.com](xiemei0801@163.com)) .  \n†These authors contributed equally to this work.  \nAbstract  \nBackground: The clinical significance of endocrine therapy (ET) in patients with estrogen receptor–low (ER-low, 1%-10%) breast cancer remains uncertain. Increasing evidence suggests that these tumors differ biologically from typical hormone receptor–positive cancers, raising questions about the true benefit of ET in this subgroup.  \nMethods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to July 1, 2025. Hazard ratios (HRs) with corresponding 95% CIs for time-to-event outcomes were extracted directly or estimated from Kaplan–Meier curves when not explicitly reported. Pooled analyses were performed using random-effects models to account for between-study heterogeneity. The protocol was registered in PROSPERO (CRD420251055521).  \nResults: A total of 6 retrospective observational studies involving 8765 patients with estrogen receptor–low breast cancer were included. Endocrine therapy was associated with improved overall survival (OS) (HR 0.81, 95% CI 0.69-0.95; P = .01; I2 = 0%) and disease-free survival (DFS) (HR 0.64, 95% CI 0.45-0.90; P = .01; I2 = 0%).  \nConclusions: Endocrine therapy was associated with improved OS and DFS in patients with estrogen receptor–low breast cancer. These findings suggest that estrogen receptor–low breast cancer should not be uniformly considered endocrineinsensitive and that routine omission of endocrine therapy should be approached cautiously. Given that the available evidence is derived from retrospective observational studies, further prospective studies are needed to identify patients most likely to benefit from endocrine therapy.  \nKey words: breast cancer; ER-low; endocrine therapy; meta-analysis.  \nImplications for Practice  \nEstrogen receptor–low breast cancer is biologically heterogeneous and often overlaps with triple-negative breast cancer, making the value of endocrine therapy uncertain. In this meta-analysis, endocrine therapy was associated with improved overall survival and disease-free survival after harmonization of effect directions across studies. These findings suggest that endocrine therapy should not be routinely omitted solely because estrogen receptor expression is low. Treatment decisions should integrate estrogen receptor percentage, clinicopathologic features, response to neoadjuvant therapy, expecte","cbCaicgZgQFxzh8H","https://ap.wps.com/l/cbCaicgZgQFxzh8H","pdf",1064437,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Implications for Practice\n# Introduction","[{\"question\":\"What clinical question does the review address?\",\"answer\":\"It evaluates the clinical significance of endocrine therapy for patients with estrogen receptor–low breast cancer, where benefit has been uncertain.\"},{\"question\":\"How were studies identified and analyzed?\",\"answer\":\"The review followed PRISMA 2020 and searched PubMed, Embase, the Cochrane Library, and Web of Science up to July 1, 2025. Effect sizes were synthesized using random-effects models and hazard ratios were extracted or estimated from Kaplan–Meier curves.\"},{\"question\":\"What survival benefits were reported for endocrine therapy?\",\"answer\":\"Endocrine therapy was associated with improved overall survival (HR 0.81, 95% CI 0.69-0.95) and disease-free survival (HR 0.64, 95% CI 0.45-0.90).\"},{\"question\":\"Why should endocrine therapy not be routinely omitted in ER-low breast cancer?\",\"answer\":\"The findings suggest improved OS and DFS, and the authors caution against uniform endocrine-insensitive assumptions. They also note evidence is based on retrospective observational studies, warranting further prospective research.\"}]","Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer - a systematic review and meta-analysis | PDF",1790089267,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c54c3d0121cdcddbefa7944cdc509b70.webp",983,1291,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5645a03b1e68b548bd468b4bd225055e.webp",982,1290,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbc5967a04b9cf436a9509defb298e4f.webp",981,1289,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6dc7da17f42abcdad31185f61415f9b.webp",980,1287]